<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2326</article-id><article-id pub-id-type="doi">10.7324/IJCRR.2017.9176</article-id><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>A Review on Lorcaserin - A Selective 5-HT Serotonin Receptor Agonist in Obesity Management&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>P.</surname><given-names>Venkatesh</given-names></name></contrib><contrib contrib-type="author"><name><surname>B.R.</surname><given-names>Venkhat Balaji</given-names></name></contrib><contrib contrib-type="author"><name><surname>K.</surname><given-names>Venu Gopal</given-names></name></contrib><contrib contrib-type="author"><name><surname>S.</surname><given-names>Vinodhini</given-names></name></contrib><contrib contrib-type="author"><name><surname>T.</surname><given-names>Vinodhini</given-names></name></contrib><contrib contrib-type="author"><name><surname>C.</surname><given-names>Vinodhini</given-names></name></contrib><contrib contrib-type="author"><name><surname>K.</surname><given-names>Chitra</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>12</day><month>09</month><year>2017</year></pub-date><volume>)</volume><issue/><fpage>37</fpage><lpage>40</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Lorcaserin is a novel anti-obesity agent. The study retrospect__ampersandsignrsquo;s the pharmacokinetic effects, mode of action, adverse drug reactions and various uses of Lorcaserin. Lorcaserin is pro-opiomelanocortin neurons stimulator present in the nucleus of hypothalamus resulting in a peak melacortin-4 receptor activity, which results in satiety and decreased food intake. Though some side effects were reported, the potential benefits of Lorcaserin outweigh the risks. Serum drug monitoring is not required. Lorcaserin is a 5HT2C receptor agonist whose property may also be studied to treat anxiety, Alzheimer__ampersandsignrsquo;s disease, depression and parkinsonism. Literature review was conducted to identify relevant studies. The study reviewed the pharmacokinetics, pharmacodynamics and clinical trials proposed so far on lorcaserin.&#13;
</p></abstract><kwd-group><kwd>Lorcaserin</kwd><kwd> 5-HT agonist</kwd><kwd> Anti-obesity</kwd></kwd-group></article-meta></front></article>
